- Home
- CORT vs VRNA Comparison
CORT vs VRNA Comparison
Compare CORT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- VRNA
- Stock Information
- Founded
- CORT 1998
- VRNA 2005
- Country
- CORT United States
- VRNA United Kingdom
- Employees
- CORT N/A
- VRNA N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- CORT Health Care
- VRNA Health Care
- Exchange
- CORT Nasdaq
- VRNA Nasdaq
- Market Cap
- CORT 7.5B
- VRNA 8.3B
- IPO Year
- CORT N/A
- VRNA 2017
- Fundamental
- Price
- CORT $71.76
- VRNA $105.79
- Analyst Decision
- CORT Strong Buy
- VRNA Buy
- Analyst Count
- CORT 4
- VRNA 11
- Target Price
- CORT $138.25
- VRNA $114.10
- AVG Volume (30 Days)
- CORT 864.0K
- VRNA 2.0M
- Earning Date
- CORT 07-31-2025
- VRNA 08-06-2025
- Dividend Yield
- CORT N/A
- VRNA N/A
- EPS Growth
- CORT N/A
- VRNA N/A
- EPS
- CORT 1.11
- VRNA N/A
- Revenue
- CORT $716,080,000.00
- VRNA $221,673,000.00
- Revenue This Year
- CORT $35.85
- VRNA $895.44
- Revenue Next Year
- CORT $35.22
- VRNA $77.76
- P/E Ratio
- CORT $64.39
- VRNA N/A
- Revenue Growth
- CORT 25.71
- VRNA N/A
- 52 Week Low
- CORT $33.34
- VRNA $24.50
- 52 Week High
- CORT $117.33
- VRNA $105.85
- Technical
- Relative Strength Index (RSI)
- CORT 52.18
- VRNA 71.65
- Support Level
- CORT $70.75
- VRNA $105.16
- Resistance Level
- CORT $74.54
- VRNA $105.46
- Average True Range (ATR)
- CORT 2.74
- VRNA 0.22
- MACD
- CORT 0.26
- VRNA -0.57
- Stochastic Oscillator
- CORT 73.13
- VRNA 92.59
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.